Legal Marijuana Could Be a Solution to the Opioid Epidemic! 1 Pharma Company That May Wish to Get Into the Weed Space

Here’s a company that may make a splash in the cannabis-based pharmaceuticals space, and it’s not a producer like Canopy Growth Corp. (TSX:WEED)!

| More on:

Ignoring the immense hype drawn by marijuana of late is hard. Canada is going to be the first G7 nation to legalize the drug, and that’s going to have a substantial positive impact on the Canadian economy, as tax revenues come pouring in. All eyes will be on Canada and its producers, like Canopy Growth Corp. (TSX:WEED), in the coming years, as the nascent industry has the opportunity to mature, but the most remarkable part about legal weed isn’t the positive effect on the economy; it’s the profound positive it’ll have on society as well.

Think about the pharmaceutical industry for a moment.

Consider the massive profits they’ve enjoyed at the expense of consumers, many of whom have had no other choice but to open their wallets and pay whatever price is commanded by a particular ailment-relieving drug that’s prescribed by a doctor. Such favourable or patented drugs are what economists refer to as “perfectly inelastic goods,” or goods whose demand doesn’t change in conjunction with its price.

If a pharmaceutical company has a patent on a drug, or if it’s been proven to be the most effective at treating a particular ailment through clinical trials, a firm has the freedom to set its price, and that’s all there is to it. And if it’s been shown to improve the quality of life for a suffering individual, they’ll pay up for it.

We’ve witnessed some greedy business practices in the past that have taken advantage of the fact that some drugs are perfectly inelastic.

Think Martin Shkreli of Turing Pharmaceuticals, Michael Pearson of Valeant Pharmceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), and Mark Thompson of Concordia International Corp. (TSX:CXR)(NYSE:CXRX). They’ve set prices through the roof, and many suffering customers have had no choice but to pay the obscene amounts for drugs or continue to suffer.

It’s not just drug pricing that’s a cause for concern, though; the more insidious part of the story is the fact that many of today’s drugs have detrimental side effects that patients may not be aware of when their doctor prescribes a specific medication to them. Patients trust their doctors, and they take the medicines prescribed to them. It’s that simple.

For many of the patients who suffer from debilitating ailments like chronic pain, opioid-based medications prescribed by doctors may lead a patient down a very dark path to opioid addiction.

You’ve probably heard the stories of people whose lives were ruined because a simple opioid prescription from their doctors ended up spiraling into a full-blown addiction that led them to seek black market opioids on the streets.

The opioid crisis is a depressing story, and the most tragic part is that many cases of unintentional addiction could have been avoiding had marijuana or cannabinoid-based medications been prescribed as a substitute.

Despite the decriminalization of medical marijuana, the drug has still had a stigma in the eyes of some physicians; in some instances, a doctor may even have the incentive to prescribe a particular medication for their benefit, whether or not it’s in the best interest of their patients.

That’s a significant reason why there’s an opioid epidemic right now, but the good news is that Canada’s legalization of marijuana will erode the taboo that’s been placed on marijuana for decades. Moreover, the education of the general public will likely increase as people become more comfortable discussing the topic of marijuana and its use in therapeutic purposes, not to mention that Canada can become a pioneer in the field of marijuana research.

With this in mind, Canadian pharmaceutical firms like Valeant ought to be interested in incorporating some marijuana-based products into its roster of drugs.

Valeant was domiciled in Canada because of tax purposes in the past, but now that the tax advantage is all but gone with U.S. corporate tax cuts, Valeant may wish to take advantage of the fact that it can produce marijuana and run clinical trials involving marijuana.

Who knows? Valeant may become like a GW Pharmaceuticals, plc as a pioneer in the field of medical marijuana research.

Stay hungry. Stay Foolish.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

person enjoys shower of confetti outside
Tech Stocks

A Top-Performing U.S. Stock That Canadian Investors Really Should Own

This top-performing U.S. stock is likely to deliver significant growth led by AI infrastructure boom, which makes it a compelling…

Read more »

chip glows with a blue AI
Tech Stocks

The AI Infrastructure Boom Is Just Getting Started: Here Are 2 Stocks to Buy

These Canadian companies are well-positioned to capitalize on growth spending on AI infrastructure and deliver significant growth.

Read more »

Oil industry worker works in oilfield
Energy Stocks

1 Canadian Energy Stocks Poised for Big Growth in 2026

This top Canadian energy stock could be the biggest winner from the recent global energy crisis. Here is why it…

Read more »

up arrow on wooden blocks
Dividend Stocks

This Canadian Dividend Stock Is Up 94% — and Still 1 of the Best on the TSX

This is a reasonably priced Canadian dividend stock for long-term wealth creation.

Read more »

Investor reading the newspaper
Stocks for Beginners

3 Resilient Canadian Stocks to Own in a Headline-Driven Market

These three Canadian stocks have their own momentum, driven by gold cash flow, logistics demand, and everyday packaging needs.

Read more »

Piggy bank on a flying rocket
Dividend Stocks

The Canadian Companies That’ve Been Quietly Raising Their Dividend Payouts

Canadian Pacific Kansas City Railway (TSX:CP) increased its dividend 17.5%!

Read more »

man gives stopping gesture
Energy Stocks

Revealed: Here’s the Only Canadian Stock I’d Refuse to Sell

This Canadian stock stands out as a rare long‑term hold thanks to its stable cash flow, reliable dividends, and essential…

Read more »

top TSX stocks to buy
Dividend Stocks

2 TSX Dividend Stocks I’d Hold for the Next Decade

Two TSX dividend stocks stand out as buy-and-hold candidates for income-focused investors.

Read more »